

Press Release

d-fine | ValGenesis

ValGenesis and d-fine: Partnership Announcement

ValGenesis and d-fine announce a new partnership to drive innovation and digitalization in Continuous Process Verification leveraging data & analytics capabilities.

Lisbon, Portugal and Frankfurt, Germany | 10/29/2024

ValGenesis, a leading solutions provider on the mission to digitalize regulatory processes in the Life Sciences, and d-fine, a European consulting firm supporting its clients in complex technological and analytical projects, announce a new partnership today.

Connected by their respective engagements in the collaborative pharma community, ValGenesis and d-fine joined forces on a mission to further drive digital innovation in regulated processes, combining expertise in technology, GxP regulation and analytics capabilities.

The first focus area in this partnership will be to unlock the potential of fully digitalized Continuous Process Verification (CPV), providing continual assurance of a state of control in commercial manufacturing and deriving insights to improve the process design. ValGenesis and d-fine will leverage process and architecture design, data and software engineering capabilities as well as powerful solutions in ValGenesis' portfolio. Following the principles of Quality by Design, digital CPV programs will be effectively delivered, to boost efficiency in operations and unlock potential in process design, with ValGenesis' Process Insight solution as digital backbone.

Bo Olsen, Senior VP of Partners at ValGenesis, said: "This partnership with d-fine marks a significant step towards the digitalization of Continuous Process Verification in pharmaceutical manufacturing. By combining our expertise in regulatory digitalization with d-fine's strength in data and analytics, we are unlocking new levels of operational efficiency and ensuring continual process improvement. Together, we are not only enhancing data integrity but also shaping the future of process design and quality management in Life Sciences."

"Linked by a common vision of seamlessly integrated workflows, we aim to seize the full potential of data and analytics in Continuous Process Verification and Process Design. Relying on our high-quality approach via automation and innovative technology, we ensure data integrity, improve operational excellence and support continual improvement in pharmaceutical manufacturing" said Martin Heitmann, Senior Manager and Expert in Life Sciences and Healthcare Digitalization at d-fine.

END

Press Release

NOTES FOR EDITORS

Press Contact

Astrid Döring
Head of Marketing & Communication

d-fine GmbH
An der Hauptwache 7
D-60313 Frankfurt/Main
+49 69 90737 0
astrid.doering@d-fine.com



Bo Olsen
Senior VP
ValGenesis

About ValGenesis

ValGenesis empowers Life Sciences companies to improve quality of life by accelerating the delivery of consistent, safe products. In 2005, ValGenesis introduced the world's first digital validation lifecycle management system. ValGenesis' VLMS® was a major step towards digitalization of compliance-based corporate validation activities. Today, ValGenesis continues to push the boundaries of innovation – enhancing and expanding its portfolio beyond validation with an end-to-end digital transformation platform.

www.valgenesis.com



Martin Heitmann
Senior Manager
d-fine

About d-fine

d-fine is a European consulting firm focused on analytical and quantitative challenges and the development of sustainable technological solutions. The combination of 1500+ employees with a strong scientific background and many years of practical experience enables us to provide tailor-made, efficient and reliable solutions for more than two hundred clients from every sector of the economy.

www.d-fine.com